Careers that change lives start here. Medtronic is a global leader in healthcare technology with a Mission to alleviate pain, restore health, and extend life. Our 95,000 employees work across more than 150 countries to put patients first — developing innovative medical technologies that improve the lives of 72+ million patients each year. Your unique talents will help shape the future of healthcare while building a career grounded in purpose, growth, and impact.

A Day in the Life

PVH Korea support for educational programs and logistics

Department: Training & Education (T&E)

Position Summary

The Korea EV/PV T&E Intern will support the planning, coordination, and execution of Healthcare Professional (HCP) education programs in Korea. The role focuses on administrative, logistical, and Korean-language coordination activities to ensure the smooth delivery of local training initiatives. The intern will work closely with the Korea T&E team, HCPs, and internal stakeholders under direct supervision.

Key Responsibilities

Support coordination and execution of EV/PV HCP education programs in Korea.
Assist with faculty and participant communications in Korean.
Coordinate program logistics, including venue arrangements, materials preparation, attendance tracking, and program documentation.
Provide on-site administrative support during training programs and events.
Support scheduling and follow-up activities with hospitals, faculty, and internal stakeholders.
Assist with preparation of training materials, participant records, and post-program reporting.
Collaborate with regional T&E team members to support local execution of educational initiatives.
Maintain accurate records and ensure timely completion of administrative tasks related to T&E programs.

Responsibilities may include the following and other duties may be assigned.

This is a temporary position.
Responsible for performing and supporting research for teams operating within a service group, product group and/ or project group.
Assists with the development, monitoring, coordination and implementation of non-technical projects as assigned.
Provides analysis, reporting and internal communication services with team members.
Develops knowledge of industry and organizational processes.

Important Note

This internship is designed to provide coordination, administrative, and logistical support for Training & Education activities. The intern will not independently deliver training, assume customer-facing ownership, or be accountable for program leadership and execution. All activities will be performed under the supervision of the T&E / Commercial team.

Physical Job Requirements

The above statements are intended to describe the general nature and level of work being performed by employees assigned to this position, but they are not an exhaustive list of all the required responsibilities and skills of this position. 

‌

Recruitment Fraud Alert

We are aware of phishing scams targeting job seekers. Please keep the following in mind:

Apply only through official Medtronic channels. All legitimate Medtronic recruiting communications come from approved Medtronic platforms and official @medtronic.com email addresses.

Medtronic will never ask for payment or sensitive personal information (such as bank account or Social Security details) during early stages of the hiring process. Any such requests are not legitimate.

If you receive a suspicious message claiming to be from Medtronic, do not respond, click links, or open attachments.

If you have any questions, concerns regarding the authenticity of a communication alleged to have been made by or on behalf of Medtronic, please contact us immediately at [email protected].

Benefits & Compensation

Medtronic offers a competitive Salary and flexible Benefits Package
A commitment to our employees lives at the core of our values. We recognize their contributions. They share in the success they help to create.We offer a wide range of benefits, resources, and competitive compensation plans designed to support you at every career and life stage.

‌

About the company

Medtronic makes medical devices and therapies to treat chronic diseases, including implantables, sensors, and diabetes management tools. Its devices interact with the body to regulate or monitor functions, such as pacemakers delivering heart stimulation and neuromodulation devices sending electrical signals. The company differentiates itself through a long history of device development and a broad portfolio, expanded via acquisitions to access new technologies and markets. Its goal is to improve patient health outcomes by providing integrated medical technologies that help manage chronic conditions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Fridley, Minnesota

Founded

1949

Get referred to Medtronic

See people who can refer or advise you

Simplify's Take

What believers are saying

Sept. 23, 2026 fiscal Q1 organic revenue rose 13.7%, led by Cardiac Ablation Solutions.
Sept. 30, 2026 Affera clearances deepen Medtronic's edge in pulsed field ablation.
Sept. 14, 2026 MiniMed exchange offer advances portfolio simplification and capital redeployment.

What critics are saying

July 15, 2026 Bio-Medicus recall exposed packaging failures in a high-risk perfusion product.
Medtronic spinal cord stimulator cases remain individual, and Schiltz's July 14, 2026 order tightens deadlines.
MiniMed separation still consumes management attention, and a weak public debut pressures execution through 2027.

What makes Medtronic unique

Sep 30, 2026 Prism-2 software tightly links Medtronic catheters, mapping, and PFA therapy.
Sept. 16, 2026 Hugo gained LigaSure robotic clearance, building a multi-platform surgical stack.
Oct. 1, 2026 Altaviva and Symplicity earned Category I CPT codes, accelerating reimbursement.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
Unlimited Paid Time Off
Paid Vacation
Paid Sick Leave
Paid Holidays
401(k) Retirement Plan
401(k) Company Match

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

2 year growth

PR Newswire

Oct 15th, 2026

Medtronic's Stealth AXiS surgical system and Corsano wearable named to TIME Best Inventions 2026

Medtronic plc has won a place on TIME's Best Inventions of 2026 list for two products: the Stealth AXiS surgical system and the Corsano multi-parameter wearable. The company announced the recognition on October 15, 2026. Stealth AXiS combines planning, navigation, and robotic-assisted execution in one platform. It supports spinal, cranial, and ear, nose, and throat procedures, and uses real-time data, advanced imaging, and AI. The Corsano wearable is made by Corsano Health B.V. and distributed by Medtronic in the US and Western Europe. It tracks pulse rate, blood oxygen saturation, respiration rate, skin temperature, and activity, giving clinicians near real-time data from hospital to home. Spot checks alone can leave patients unmonitored 96% of the time, according to the company.

SPINEMarketGroup

Oct 15th, 2026

Medtronic Named to TIME Best Inventions of 2026 List for Stealth AXiS(TM) surgical system and Corsano(TM)* multi-parameter wearable.

Medtronic Named to TIME Best Inventions of 2026 List for Stealth AXiS(TM) surgical system and Corsano(TM)* multi-parameter wearable. GALWAY, Ireland, Oct. 15, 2026 /PRNewswire/ - Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the Stealth AXiS(TM) surgical system and the Corsano(TM)* multi-parameter wearable have been named to the TIME Best Inventions of 2026 list. The annual award highlights the most impactful new products and ideas of the year, assessed by TIME editors. The dual recognition highlights the Medtronic enterprise-wide commitment to transforming healthcare through connected technologies that help clinicians make more informed decisions and improve care delivery. Advancing connected surgery with Stealth AXiS(TM) The Stealth AXiS(TM) surgical system was recognized for bringing planning, navigation, and robotic-assisted execution together in a single platform designed for complex procedures. The system addresses challenges in surgery, where technologies for planning, imaging, navigation, and execution are often fragmented across multiple systems. Built within Medtronic's AiBLE(TM) smart ecosystem, the Stealth AXiS(TM) system supports spinal, cranial, and ear, nose, and throat (ENT) procedures by integrating real-time data, advanced imaging, and AI-based capabilities into the surgical workflow to create a more connected approach to care across the surgical journey. "Being named a TIME Best Invention is meaningful recognition of the innovation behind the Stealth AXiS(TM) system and our commitment to advancing the connected surgical ecosystem," said Michael Carter, president of the Cranial and Spinal Technologies operating unit within the Neuroscience Portfolio at Medtronic. "Our goal is to help surgical teams work with greater connectivity and intelligence by bringing planning, navigation, and robotics together in one integrated platform." Expanding continuous patient monitoring with Corsano(TM)* multi-parameter wearable The Corsano(TM)* multi-parameter wearable was recognized for its ability to extend clinical visibility beyond traditional bedside monitoring through a lightweight, tetherless wearable designed to capture key vital parameters and trending information to inform clinical decision making. Manufactured by Corsano Health B.V. and distributed in the U.S. and Western Europe by Medtronic, the wearable provides clinicians access to patient data in near real time, from the hospital to the home setting. While spot checking alone can leave patients unmonitored 96% of the time[1], the medical-grade wearable monitors pulse rate, blood oxygen saturation (SpO[2]), respiration rate, skin temperature, and activity, helping clinicians access timely patient information while enabling patient mobility and comfort. "This recognition on the TIME Best Inventions list is a testament to what's made possible by the next generation of patient monitoring," said Kate Benedict, president of the Acute Care & Monitoring operating unit within the Medical Surgical Portfolio at Medtronic. "The Corsano(TM)* multi-parameter wearable meaningfully expands our portfolio of wearable patient monitoring solutions and reflects our commitment to helping clinicians stay connected to patient data wherever care is delivered, enabling more informed decisions with patient insights." About Medtronic Bold thinking. Bolder actions. The Spine Market Group is Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Its Mission - to alleviate pain, restore health, and extend life - unites a global team of 95,000+ passionate people across more than 150 countries. Its technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, surgical tools, patient monitoring systems, and more. Powered by its diverse knowledge, insatiable curiosity, and desire to help all those who need it, The Spine Market Group deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from The Spine Market Group as The Spine Market Group empower insight-driven care, experiences that put people first, and better outcomes for its world. In everything The Spine Market Group do, The Spine Market Group is engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn. About the Cranial & Spinal Technologies Business at Medtronic As the global market leader, Medtronic Cranial and Spinal Technologies is transforming the standard of care in spine and cranial surgery by putting patients first and addressing the complex challenges faced by spine and neurosurgeons. With a portfolio of 150 products covering more than 20 pathologies, The Spine Market Group serve over 4 million patients annually. Building on a legacy of innovation, its AiBLE(TM) ecosystem integrates advanced technologies, data, and AI with a patient-centric approach, offering customizable solutions to enhance surgical precision, improve workflow efficiency, and pursue better outcomes, before, during, and beyond surgery. About Acute Care & Monitoring At Medtronic Acute Care & Monitoring, The Spine Market Group put patients first by designing patient monitoring and airway management technologies that support care in the moments that matter. By simplifying clinical decision making, workflows, and operational performance, The Spine Market Group help care teams stay focused on patients while helping organizations create sustainable value from their technology investments. The Spine Market Group do this to support its vision: to enable personalized patient care, anytime, anywhere. For more information, visit medtronic.com/ACM. About the Ear, Nose, & Throat Business at Medtronic Medtronic's Ear, Nose, and Throat (ENT) business is the global market leader in ENT, delivering innovative technologies that impact nearly 3 million patients each year. For more than 25 years, The Spine Market Group has collaborated with physicians to advance care across the specialty. Its portfolio supports surgical procedures related to chronic rhinosinusitis and head and neck cancers, spanning surgical navigation, tissue health, powered instruments, localized drug delivery, intraoperative nerve monitoring, and parathyroid detection. As the global leader in ENT navigation since the introduction of the LandmarX(TM) image-guided surgery system in 1998, The Spine Market Group continue to advance the field with next-generation platforms including the Stealth AXiS(TM) Surgical System. For more information, visit Medtronic.com/AXiSENT. About Corsano Health Corsano Health B.V. is a leading MedTech company that creates, manufactures, and sells advanced real-time remote patient monitoring solutions. With a CE-MDR medically certified system and FDA clearance, the Corsano(TM) multi-parameter wearable is setting new standards for continuous monitoring, focusing on its mission to lower healthcare costs and support clinical teams in improving outcomes and patient experiences. For more information, visit https://corsano.com/. *The Corsano(TM)* multi-parameter wearable is manufactured by Corsano Health B. V. and distributed by Medtronic. The Corsano(TM) multi-parameter wearable should not be used as the sole basis for diagnosis or therapy and is intended only as an adjunct in patient assessment. It is not intended for use in high-acuity environments or on acutely ill cardiac patients with potential to develop life-threatening arrhythmias, or for SpO[2] monitoring in conditions of high motion or low perfusion. [1] Curry and Jungquist: A critical assessment of monitoring practices, patient deterioration, and alarm fatigue on inpatient wards: a review. Patient Safety in Surgery 2014 8:29. Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results. SOURCE Medtronic plc

Flywheel Publishing, LLC

Oct 14th, 2026

Medtronic pays more today. Abbott raises its dividend faster. Which stock wins?

Medtronic pays more today. Abbott raises its dividend faster. Which stock wins? Both are Dividend Kings with decades of consecutive raises, but Medtronic and Abbott reward income investors in fundamentally different ways, and choosing the wrong one in retirement could cost you more than you expect. Medtronic (NYSE:MDT | MDT Price Prediction) or Abbott Laboratories (NYSE:ABT): which medical device dividend stock better suits income needs in retirement? Both stocks outperformed competitors on a strong trading day Monday, but they pay income investors in very different ways. Medtronic offers the higher current payout and covers it with cleaner cash flow. Abbott raises its dividend faster. Medtronic's higher, better-covered yield carries more weight when you live on the checks. Yield: Medtronic pays more per dollar invested. Medtronic's forward annual dividend of $2.88 yields 3.22% with the stock at $91.93. Abbott's forward dividend of $2.52 yields 2.49% at $102.35. Medtronic also costs less: about 15x forward earnings versus 17x for Abbott, and 23x trailing earnings versus 34x. Winner: Medtronic. More income up front, at a lower multiple. Dividend safety: Medtronic's coverage holds up better. On trailing GAAP EPS of $4.07, Medtronic pays out about 70%. Abbott pays out roughly 82% of its $3.03. The $21 billion Exact Sciences acquisition is weighing on Abbott's GAAP results: second-quarter GAAP EPS fell to $0.53 from $1.01, interest expense rose to $299M from $50M, and the company recorded a $385M legal reserve. On adjusted guidance the two look closer. Medtronic's dividend is about 48% of its $5.94 to $6.00 fiscal 2027 guide's low end, and Abbott's is about 46% of its $5.45 to $5.60 range. Free cash flow gives Medtronic the edge. Medtronic generated $5.43B of free cash flow in fiscal 2026, and first-quarter free cash flow of $1.29B covered $921 million in dividends, a payout of roughly 71%. Abbott's cash flow commentary was limited to guidance that cash generation is "likely going to put us ahead of our January forecast for the year." The businesses behind the payouts carry different revenue mixes. Medtronic sells procedure hardware: pacemakers in a Cardiac Rhythm Management unit with more than $5.5 billion in annual revenue, ablation systems growing 88%, a surgical business above $6 billion, and spine robotics. Separating its lower-margin Diabetes unit should lift operating margin by about 100 basis points. Abbott spreads its revenue more widely: devices brought in $5.85B of $12.59B in quarterly revenue, with diagnostics (now including Cologuard), branded generics, and nutrition making up the rest. That diversity helps, but nutrition declined 3.1% and U.S. Structural Heart sales fell 9.8%. Free Report, Just Released Why Didn't ABT Make The Top 10 List? 24/7 Wall St has helped investors make money for over two decades, and our top analysts just finished ranking the definitive Top 10 Stocks To Buy Now. Not the ten biggest companies. Not the ten everyone is arguing about. The ten best stocks to buy right now. And ABT didn't make the cut! The report is free, and you can see why we think each stock is a top investment today. Winner: Medtronic. Dividend growth: Abbott compounds faster. Abbott just made its 54th consecutive year of increases, and Medtronic its 49th, putting both firmly in Dividend King territory (we ranked ten Kings by valuation in a free report). Dividend records back to 1999 show annual raises for both, with one exception: Abbott's quarterly payment fell from $0.51 to $0.14 in 2013, when it spun off AbbVie (NYSE:ABBV). Abbott counts its run as unbroken on a combined basis. Abbott wins easily on pace. Its 2026 raise from $0.59 to $0.63 came to about 6.8%. Medtronic went from $0.71 to $0.72, about 1.4%. Since 2016, Abbott's quarterly payment is up roughly 142%, compared with 67% for Medtronic. Winner: Abbott. Verdict: Medtronic is the retiree's dividend stock. Medtronic wins for retirement-focused income investors. It wins two of the three areas, and those two matter most once you start drawing income: a higher starting yield and cash coverage you can actually see. Its small raises are the weak spot, but the business underlying is speeding up. Fiscal 2026 revenue rose 8.43%, and management raised its fiscal 2027 organic growth guide to 7.25% to 7.75%. With the margin lift from the Diabetes separation on top, Medtronic has room to raise faster. Abbott suits investors with 15 or more years before retirement who reinvest their dividends. Its price return of 200.92% over ten years crushes Medtronic's 45.41%, and a 21.01% drop over the past year leaves the stock below its old highs. For income you need now, though, Medtronic pays more and covers it better. Got $1,000? Before you buy ABT, read this. If you have cash sitting in your account right now, give this two minutes. After more than two decades of helping investors beat the market, our top analysts at 24/7 Wall St. put together a definitive report on the Top 10 Stocks To Buy Today. And ABT wasn't one of them. They combed the entire market. It's not 10 ideas, not 10 stocks everyone is talking about, it's what their research points to as the 10 best stocks to buy right now, and it's free. Read more here and see which stocks made the list ->> Chris Lange Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology. His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups. When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.

The Healthcare Technology Report

Oct 12th, 2026

Medtronic hires former Recor CEO Lara Barghout to lead Cardiology unit.

Medtronic hires former Recor CEO Lara Barghout to lead Cardiology unit. Published. October 12, 2026 Medtronic has put former Recor Medical chief executive Lara Barghout in charge of its Interventional Cardiology Therapies business, bringing in a leader who previously oversaw a competing hypertension device. Her remit covers structural heart, coronary, and hypertension management products. During her Recor tenure, the Paradise device became the first renal denervation system to receive FDA approval for uncontrolled high blood pressure, MedTech Dive reported. Medtronic's competing Symplicity Spyral secured approval weeks later. "Lara brings proven leadership in the cardiovascular space," Medtronic told MedTech Dive in an emailed statement. Her appointment follows a reorganization dividing the cardiovascular portfolio into four businesses, including the unit she now leads. Earlier roles included senior vice president and head of advanced therapies at Siemens Healthineers and an executive position at Terumo Cardiovascular. She joined Recor as president and chief executive in January 2023 and left in February 2026. Other leadership changes preceded the hire. Jason Fontana, formerly vice president and general manager of renal denervation, announced his departure. Jason Weidman, previously president of coronary and renal denervation, left in the spring to become Teleflex CEO.

Yahoo Finance

Oct 11th, 2026

Medtronic trades at 14.4x forward earnings as quarterly revenue jumps 13.7% to $9.8B

Medtronic shares have fallen more than 7% in the past 12 months, while the broader market gained 17%. At $86.38, the stock trades at a forward price-to-earnings ratio of about 14.4. The medical-device maker raised its fiscal 2027 outlook in September. It now expects organic revenue growth of 7.25% to 7.75% and non-GAAP diluted earnings per share of $5.94 to $6.00. First-quarter organic revenue rose 13.7% to $9.8 billion. Cardiovascular grew 18.9%, diabetes 14.9%, and neuroscience 9.3%. However, an extra fiscal week added about $570 million to organic growth, flattering the result. Whether the momentum lasts will decide if the stock re-rates.

Medtronic

Graduate Intern - Non-Tech

About the job